Overview
The ReceptIVFity acts as a timing-tool for prediction of optimal pregnancy chances and provides insight into the patient's current (two months after sampling) success rate of an IVF/IVF-ICSI treatment. Benefits of physician decision treatment in case of an unfavorable vaginal profile and a low chance of achieving a pregnancy include reducing unnecessary morbidity and treatment cycles, stress and disappointment, while increasing efficacy of the treatment and lowering the costs needed to achieve a pregnancy.
The goal of this prospective, clinical non-invasive randomized controlled study, with an additional observational study arm (for women of non-European origin) in naïve IVF or IVF/ICSI patients is to evaluate the efficiency of Shared Decision Making compared to Physician Decision in terms of
- the success probability of an IVF cycle,
- the proportion of women with a successful pregnancy
- the number of unsuccessful IVF cycles.
Randomization component Women of European origin will be randomized 1:1 to either the shared decision group or the physician decision group. All women of European origin may undergo one to three cycles of IVF/IVF-ICSI reimbursed by the health insurance. The follow-up ends after the outcome of the last of these cycles has been determined. The desired outcome of the IVF or IVF/ICSI treatment is a successful pregnancy, i.e., a pregnancy with a heart-beat at 12 weeks of gestation.
Observational component Women of non-European origin are invited to take part in an observational component of this study. Without further evaluation of the results of their vaginal microbiome, they will continue with the IVF/IVF-ICSI cycle. Women eligible for participation are naïve patients and the follow-up ends after the outcome of the first IVF/IVF-ICSI cycle has been determined.
Eligibility
Inclusion Criteria:
- Naïve IVF or IVF/ICSI patients
- Indication for an IVF or IVF-ICSI procedure.
- 18 years < age < 43 years.
- Willing to provide a vaginal swab with the ReceptIVFity test.
- Willing to provide informed consent.
Exclusion Criteria:
- The use of hormonal contraceptives at the time of taking the test.
- The use of antibiotic treatment at the time of taking the test.
- Emergency IVF for cancer or other reasons.
- Women with endometriosis pre-treated with an Gn-RH analogue.
- Women having IVF for egg preservation reasons.